跳转至内容
Merck
所有图片(1)

文件

MABC1151

Sigma-Aldrich

Anti-NY-ESO-1 Antibody, clone D8.38

clone D8.38, from mouse

别名:

Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, CT6.1, L antigen family member 2, LAGE-2

登录查看公司和协议定价


About This Item

分類程式碼代碼:
12352203
eCl@ss:
32160702
NACRES:
NA.41

生物源

mouse

品質等級

抗體表格

purified antibody

抗體產品種類

primary antibodies

無性繁殖

D8.38, monoclonal

物種活性

human

技術

immunohistochemistry: suitable (paraffin)

同型

IgG1κ

UniProt登錄號

運輸包裝

ambient

目標翻譯後修改

unmodified

基因資訊

human ... CTAG1A(246100)

一般說明

Cancer/testis antigen 1 (UniProt: P78358; also known as Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, CT6.1, L antigen family member 2, LAGE-2) is encoded by the CTAG1A (also known as CTAG, CTAG1, ESO1, LAGE2, LAGE2A, CTAG1B, LAGE2B) gene (Gene ID: 1485; 246100) in human. NY-ESO-1 is a human tumor antigen of the cancer/testis family that is highly expressed in many poor-prognosis melanomas and in other cancer types. However, it is not detected in non-malignant tissues with the exception of germ cells and trophoblasts. It contains a C-terminal hydrophobic tail that potentially serves as membrane-associated domain. NY-ESO-1 is expressed from 18 weeks until birth in human fetal testis and in adult testis it is strongly expressed in spermatogonia and in primary spermatocytes, but not in post-meiotic cells or in testicular somatic cells. Although the exact function of NY-ESO-1 is still not clear, it has been speculated it might contribute to certain properties, such as immortality, self-renewal, migratory ability, and capacity to invade that favor tumor cell survival. On the basis of its immunogenicity, NY-ESO-1 is considered as one of the most attractive antigens for cancer immunotherapy. T cells engineered to express an affinity-enhanced T cell receptor (TCR) recognizing a naturally processed peptide shared by the cancer-testis antigens NY-ESO-1 and LAGE-1 have been considered as an attractive method for treatment of myeloma and enhance long-term survival of cells.

特異性

Clone D8.38 specifically targets a sequence in the N-terminal region and detects Cancer/testis antigen 1 (NY-ESO1) in human testis

免疫原

A full length recombinant human NY-ESO-1 protein.
Epitope: domain of:

應用

Detect NY-ESO-1, LAGE-1 using this mouse monoclonal Anti-NY-ESO-1 antibody, clone D8.38, Cat. No. MABC1151. Validated for use in Immunohistochemistry (Paraffin).
Immunohistochemistry Analysis: A 1:250-1,000 dilution from a representative lot detected NY-ESO-1 in human testis tissue.

Immunohistochemistry Analysis: A representative lot detected NY-ESO-1 in Immunohistochemistry applications. (Yakirevich, E., et. al. (2003). Clin Cancer Res. 9(17):6453-60; Bujas, T., et. al. (2011). Eur J Histochem. 55(1):e7; Bolli, M., et. al. (2005). Int J Cancer. 115(6):960-6; Groeper, C., et. al. (2007). Int J Cancer. 120(2):337-43).
Research Category
Apoptosis & Cancer

品質

Evaluated by Immunohistochemistry in human testis tissue.

Immunohistochemistry Analysis: A 1:250 dilution of this antibody detected NY-ESO-1 in human testis tissue.

標靶描述

17.99 kDa calculated.

外觀

Protein G purified
Format: Purified
Purified mouse monoclonal antibody IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

儲存和穩定性

Stable for 1 year at 2-8°C from date of receipt.

其他說明

Concentration: Please refer to lot specific datasheet.

免責聲明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our 产品选型工具.

儲存類別代碼

12 - Non Combustible Liquids

水污染物質分類(WGK)

WGK 1


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Martine Bloemendal et al.
Oncoimmunology, 11(1), 2015113-2015113 (2022-12-17)
We evaluated the immunological responses of lymph-node involved (stage III) melanoma patients to adjuvant dendritic cell vaccination with subsets of naturally occurring dendritic cells (nDCs). Fifteen patients with completely resected stage III melanoma were randomized to receive adjuvant dendritic cell

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门